miR128 is downregulated in PD patients’ sera, and its supplementation on 6-OHDA-treated cells can reestablish balance in apoptotic pathways, reducing FasL and PUMA expression, increasing FOXO3a expression and reducing caspases 3, 8, and 9 activities. Here, FASLG is linked to Parkinson disease.